tiprankstipranks
Trending News
More News >
Fusen Pharmaceutical Co., Ltd. (HK:1652)
:1652
Hong Kong Market
Advertisement

Fusen Pharmaceutical Co., Ltd. (1652) AI Stock Analysis

Compare
0 Followers

Top Page

HK:1652

Fusen Pharmaceutical Co., Ltd.

(1652)

Rating:43Neutral
Price Target:
HK$0.50
▲(38.89%Upside)
Fusen Pharmaceutical Co., Ltd. faces significant financial challenges, with declining revenues, operational inefficiencies, and severe liquidity issues being the most impactful factors. The technical analysis indicates a potential downtrend, further pressuring the stock. The valuation is weak due to negative earnings and no dividend yield. These factors collectively contribute to a low overall stock score.

Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)

Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company DescriptionFusen Pharmaceutical Co., Ltd. (1652) is a China-based company primarily engaged in the research, development, production, and sale of pharmaceutical products. The company operates within the pharmaceutical sector, focusing on the manufacturing of both traditional Chinese medicines and chemical drugs. Fusen Pharmaceutical offers a diverse range of products, including over-the-counter (OTC) medicines and prescription drugs, serving various therapeutic areas.
How the Company Makes MoneyFusen Pharmaceutical Co., Ltd. generates revenue through the sale of its pharmaceutical products, which include traditional Chinese medicines and chemical drugs. The company's revenue streams are primarily derived from the sale of over-the-counter (OTC) medications and prescription drugs to hospitals, pharmacies, and healthcare providers. Additionally, the company may engage in collaborations or partnerships with other pharmaceutical firms to enhance its research and development capabilities, potentially leading to new product offerings and expanded market reach. Fusen Pharmaceutical's earnings are influenced by factors such as product demand, pricing strategies, regulatory approvals, and market expansion efforts.

Fusen Pharmaceutical Co., Ltd. Financial Statement Overview

Summary
Fusen Pharmaceutical Co., Ltd. faces significant financial challenges. Declining revenues and profitability, increased leverage, and zero or negative free cash flow underscore severe liquidity risks. The negative net income and operating cash flow highlight ongoing operational difficulties.
Income Statement
40
Negative
The company's income statement shows a troubling trend with declining revenues from 2023 to 2024 and negative net income for both years. Gross profit margin deteriorated significantly from 2023 to 2024, reflecting inefficiencies or pricing pressures. The EBIT margin turned negative in 2024, indicating operational challenges. The revenue growth rate was negative, suggesting a contraction phase.
Balance Sheet
55
Neutral
The balance sheet reveals a moderately leveraged position with a debt-to-equity ratio of approximately 1.04 in 2024. The equity ratio is stable, but stockholders' equity decreased over the period, indicating potential financial strain. Return on equity was negative in 2024, further signaling profitability issues.
Cash Flow
35
Negative
The cash flow analysis highlights severe liquidity challenges with zero free cash flow in 2024 and negative operating cash flow in 2023. The free cash flow growth rate is not calculable due to zero cash flow in 2024, and the operating cash flow to net income ratio is also indeterminate, underscoring cash generation issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue326.03M565.61M491.76M385.66M486.85M
Gross Profit162.64M299.51M225.02M211.13M266.07M
EBITDA-39.07M18.93M49.90M86.84M110.30M
Net Income-188.78M-36.28M-34.65M16.64M70.13M
Balance Sheet
Total Assets1.24B1.34B1.35B1.24B1.24B
Cash, Cash Equivalents and Short-Term Investments21.06M34.85M128.11M81.70M312.53M
Total Debt383.69M344.12M228.38M240.69M198.50M
Total Liabilities869.80M781.52M737.38M582.39M583.10M
Stockholders Equity369.67M563.52M614.17M658.17M659.44M
Cash Flow
Free Cash Flow57.43M-161.84M86.63M-62.37M94.56M
Operating Cash Flow133.73M-73.33M110.49M47.77M153.21M
Investing Cash Flow-163.42M-108.32M-13.13M-282.98M-68.20M
Financing Cash Flow15.99M88.50M-51.77M20.53M-116.33M

Fusen Pharmaceutical Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.36
Price Trends
50DMA
0.36
Negative
100DMA
0.32
Positive
200DMA
0.53
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
39.24
Neutral
STOCH
74.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1652, the sentiment is Negative. The current price of 0.36 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.36, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.24 is Neutral, neither overbought nor oversold. The STOCH value of 74.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1652.

Fusen Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
HK$711.48M6.888.81%5.95%5.79%-43.49%
54
Neutral
HK$519.17M
48
Neutral
HK$185.17M-7.93%1.13%38.41%
48
Neutral
HK$189.57M-26.80%-6.09%66.59%
46
Neutral
C$198.38M-2.33-23.14%2.83%20.73%-1.08%
43
Neutral
HK$264.68M-40.39%-43.73%-434.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1652
Fusen Pharmaceutical Co., Ltd.
0.36
-0.62
-63.27%
HK:8622
Huakang Biomedical Holdings Company Limited
0.36
0.23
176.92%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.84
-0.24
-22.22%
HK:1498
PuraPharm Corp. Ltd.
0.48
-0.22
-31.43%
HK:1011
China NT Pharma Group Co., Ltd.
0.71
0.43
153.57%

Fusen Pharmaceutical Co., Ltd. Corporate Events

Fusen Pharmaceutical Reports Unanimous Approval of AGM Resolutions
May 29, 2025

Fusen Pharmaceutical Company Limited, a pharmaceutical company incorporated in the Cayman Islands, announced that all proposed resolutions at its Annual General Meeting held on May 29, 2025, were passed unanimously by shareholders. These resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to the board for share issuance and repurchase. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued operational stability and strategic flexibility.

Fusen Pharmaceutical Announces Change in Shareholding Structure
May 26, 2025

Fusen Pharmaceutical Co., Ltd. has announced a significant change in its shareholding structure following the passing of Mr. Cao, the former chairman and investment manager of Fusen Trust. The Vesting Arrangement has transferred control of the voting rights of Fusen Trust Shares to Mr. Cao Zhiming, increasing his voting rights to 45.29% of the total issued shares. This change has triggered a potential requirement for a mandatory general offer under the Takeovers Code, but Mr. Cao Zhiming has obtained a waiver from this obligation.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025